Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
The Majority of Non-Prescribers Anticipate Prescribing Gilotrif Within the Next Three Months, According to Findings from Decision Resources Group
BURLINGTON, Mass., April 24, 2014 /PRNewswire/ -- Decision Resources Group finds that at six months post-launch in the United States, 49 percent of surveyed U.S. medical oncologists have prescribed Boehringer Ingelheim's irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Gilotrif, for NSCLC patients outside of clinical trials. Among current non-prescribers of Gilotrif, just over half expects to prescribe Gilotrif to their EGFR-mutation-positive NSCLC patients within the next three months.
Other key findings from the LaunchTrends® Gilotrif report:
Comments from Decision Resources Group Analyst Jennifer Bamford:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.